Anita W. Rijneveld

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

Journal: American journal of hematology

Published: June 10, 2026

Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries.

Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries.

Journal: Blood cancer journal

Published: December 19, 2025

Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study.

Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study.

Journal: Haematologica

Published: September 02, 2025

Oxidantscan: A novel biomarker to assess red blood cell susceptibility to oxidative stress in sickle cell disease.

Oxidantscan: A novel biomarker to assess red blood cell susceptibility to oxidative stress in sickle cell disease.

Journal: Blood cells, molecules & diseases

Published: August 29, 2025

The right glucarpidose?

The right glucarpidose?

Journal: Blood advances

Published: July 07, 2025

Metabolomics in sickle cell disease: Current knowledge and gaps - A scoping review.

Metabolomics in sickle cell disease: Current knowledge and gaps - A scoping review.

Journal: Blood reviews

Published: June 25, 2025

Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial.

Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial.

Journal: The Lancet. Haematology

Published: April 10, 2025

Iron Deficiency in HbSC Disease Treated With Repetitive Phlebotomy Is Associated With Fewer Sickle Cell Disease-Related Complications.

Iron Deficiency in HbSC Disease Treated With Repetitive Phlebotomy Is Associated With Fewer Sickle Cell Disease-Related Complications.

Journal: American journal of hematology

Published: March 25, 2025

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.

Journal: Blood

Published: January 16, 2025

COVID- 19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNet.

COVID- 19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNet.

Journal: Orphanet journal of rare diseases

Published: January 04, 2025

Red blood cell pyruvate kinase properties in Townes and Berkeley sickle cell disease mouse models - Of mice and men.

Red blood cell pyruvate kinase properties in Townes and Berkeley sickle cell disease mouse models - Of mice and men.

Journal: Blood cells, molecules & diseases

Published: November 19, 2024

Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease.

Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease.

Journal: American journal of hematology

Published: November 19, 2024

Showing 1-12 of 56

Last Updated: 09/26/2026